JP2017512498A - 複数成分複数段階マラリアワクチン - Google Patents

複数成分複数段階マラリアワクチン Download PDF

Info

Publication number
JP2017512498A
JP2017512498A JP2017501492A JP2017501492A JP2017512498A JP 2017512498 A JP2017512498 A JP 2017512498A JP 2017501492 A JP2017501492 A JP 2017501492A JP 2017501492 A JP2017501492 A JP 2017501492A JP 2017512498 A JP2017512498 A JP 2017512498A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
recombinant
pfama1
mixture according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017501492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512498A5 (enExample
Inventor
ボー，アレクサンダー
シュピーゲル，ホルガー
エドグー，グーヴェン
ベイス，ベロニーク
マークス サック
マークス サック
レイマン，アンドレア
フィッシャー，レイナー
Original Assignee
フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー．フアー．
フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー．フアー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー．フアー．, フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー．フアー． filed Critical フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー．フアー．
Publication of JP2017512498A publication Critical patent/JP2017512498A/ja
Publication of JP2017512498A5 publication Critical patent/JP2017512498A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G01N2333/445—Plasmodium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2017501492A 2014-03-28 2015-03-27 複数成分複数段階マラリアワクチン Pending JP2017512498A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461972002P 2014-03-28 2014-03-28
US61/972,002 2014-03-28
EP14001155.2A EP2923709A1 (en) 2014-03-28 2014-03-28 Multi-component-multistage malaria vaccine
EP14001155.2 2014-03-28
PCT/EP2015/056693 WO2015144874A1 (en) 2014-03-28 2015-03-27 Multi-component-multistage malaria vaccines

Publications (2)

Publication Number Publication Date
JP2017512498A true JP2017512498A (ja) 2017-05-25
JP2017512498A5 JP2017512498A5 (enExample) 2018-04-26

Family

ID=50396848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501492A Pending JP2017512498A (ja) 2014-03-28 2015-03-27 複数成分複数段階マラリアワクチン

Country Status (5)

Country Link
US (1) US10183066B2 (enExample)
EP (2) EP2923709A1 (enExample)
JP (1) JP2017512498A (enExample)
CA (1) CA2940461A1 (enExample)
WO (1) WO2015144874A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021060862A1 (ko) * 2019-09-24 2021-04-01 고려대학교 세종산학협력단 후코이단을 유효성분으로 포함하는 말라리아 예방 또는 치료용 약학적 조성물
US11273212B2 (en) 2016-11-11 2022-03-15 Sumitomo Dainippon Pharma Co., Ltd. Malaria vaccine
JPWO2023157880A1 (enExample) * 2022-02-18 2023-08-24

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2992895A1 (en) 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
EP3081575A1 (en) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium parasite antibodies
JP2020028219A (ja) * 2016-11-11 2020-02-27 大日本住友製薬株式会社 マラリアワクチン
EP3585888A4 (en) * 2017-02-27 2020-10-21 The Walter and Eliza Hall Institute of Medical Research MALARIA VACCINE AND ITS PRODUCTION PROCESSES
US20180348218A1 (en) * 2017-06-05 2018-12-06 Tokitae Llc Serology assay for recent malaria infection
WO2018237339A1 (en) * 2017-06-22 2018-12-27 The Government Of The United States Of America As Represented By The Secretary Of The Army Nyvac-based plasmodium malaria vaccine
WO2022045173A1 (ja) 2020-08-26 2022-03-03 国立大学法人愛媛大学 抗マラリア原虫抗体
GB202301244D0 (en) * 2023-01-27 2023-03-15 Univ Oxford Innovation Ltd Vaccine
WO2024249116A1 (en) * 2023-05-26 2024-12-05 Seattle Children's Hospital D/B/A Seattle Children's Research Institute A multi-stage vaccine antigen for malaria
WO2025024337A1 (en) * 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
CN118207228B (zh) * 2024-03-21 2025-03-14 中国科学院上海免疫与感染研究所 一种防治结合的多时期双靶点串联疟疾mRNA疫苗

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041216A2 (en) * 2005-09-30 2007-04-12 Seattle Biomedical Research Institute Plasmodium liver stage antigens
WO2010037063A2 (en) * 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Plasmodium vaccines, antigens, compositions and methods
US20100291095A1 (en) * 2004-08-03 2010-11-18 Institut Pasteur Identification of a conserved region of plasmodium falciparum msp3 targeted by biologically active antibodies
WO2012170125A2 (en) * 2011-06-06 2012-12-13 The Regents Of The University Of California Algal produced malarial transmission blocking vaccines
JP2013543721A (ja) * 2010-09-27 2013-12-09 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア コンセンサス抗原コンストラクトおよびそれらから作製されるワクチン、ならびにそれらを使用するマラリアの治療方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
EP2346523A4 (en) 2008-10-01 2014-12-31 Us Health MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
CN102559613B (zh) * 2012-01-10 2014-04-23 特菲(天津)生物医药科技有限公司 一种恶性疟疾疫苗及其制备方法
DE102012013860A1 (de) 2012-07-05 2014-01-09 Thomas Dandekar DNA-arme Trypanosomen zur therapeutischen und diagnostischen Verwendung (DAT)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291095A1 (en) * 2004-08-03 2010-11-18 Institut Pasteur Identification of a conserved region of plasmodium falciparum msp3 targeted by biologically active antibodies
WO2007041216A2 (en) * 2005-09-30 2007-04-12 Seattle Biomedical Research Institute Plasmodium liver stage antigens
WO2010037063A2 (en) * 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Plasmodium vaccines, antigens, compositions and methods
JP2013543721A (ja) * 2010-09-27 2013-12-09 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア コンセンサス抗原コンストラクトおよびそれらから作製されるワクチン、ならびにそれらを使用するマラリアの治療方法
WO2012170125A2 (en) * 2011-06-06 2012-12-13 The Regents Of The University Of California Algal produced malarial transmission blocking vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LAUREN SCHWARTZ; GRAHAM V BROWN; BLAISE GENTON; VASEE S MOORTHY: "A REVIEW OF MALARIA VACCINE CLINICAL PROJECTS BASED ON THE WHO RAINBOW TABLE", MALARIA JOURNAL, vol. VOL:11, NR:1, JPN5017003995, 9 January 2012 (2012-01-09), GB, pages 11 - 1, ISSN: 0004035636 *
MAHAJAN B; BERZOFSKY J A; BOYKINS R A; MAJAM V; ET AL: "MULTIPLE ANTIGEN PEPTIDE VACCINES AGAINST PLASMODIUM FALCIPARUM MALARIA", INFECTION AND IMMUNITY, vol. VOL:78, NR:11, JPN5017003994, November 2010 (2010-11-01), pages 4613 - 4624, ISSN: 0004035635 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273212B2 (en) 2016-11-11 2022-03-15 Sumitomo Dainippon Pharma Co., Ltd. Malaria vaccine
WO2021060862A1 (ko) * 2019-09-24 2021-04-01 고려대학교 세종산학협력단 후코이단을 유효성분으로 포함하는 말라리아 예방 또는 치료용 약학적 조성물
JPWO2023157880A1 (enExample) * 2022-02-18 2023-08-24
WO2023157880A1 (ja) * 2022-02-18 2023-08-24 国立大学法人金沢大学 マラリアワクチン及びマラリア予防・治療方法
JP7649504B2 (ja) 2022-02-18 2025-03-21 国立大学法人金沢大学 マラリアワクチン及びマラリア予防・治療方法

Also Published As

Publication number Publication date
US20170106071A1 (en) 2017-04-20
US10183066B2 (en) 2019-01-22
EP2923709A1 (en) 2015-09-30
WO2015144874A1 (en) 2015-10-01
CA2940461A1 (en) 2015-10-01
EP3122373A1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
US10183066B2 (en) Multi-component-multistage malaria vaccines
EP2988776B1 (en) Novel vaccines against apicomplexan pathogens
Farrance et al. A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum
JP2017512498A5 (enExample)
Farrance et al. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity
US9109040B2 (en) Treatment and prevention of malaria
Blagborough et al. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax
US20070003562A1 (en) GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
US9919040B2 (en) Soluble recombinant plasmodium falciparum circumsporozoite protein, use in vaccines, methods of making and uses thereof
US9884101B2 (en) Treatment and prevention of malaria
Parzych et al. Evaluation of a plasmodium-specific carrier protein to enhance production of recombinant Pf s25, a leading transmission-blocking vaccine candidate
JP2017527293A (ja) 三成分多段階マラリアワクチン
US20180311326A1 (en) Immunoassemblin (ia) protein complexes
Somanathan et al. Process development and preclinical evaluation of a major Plasmodium falciparum blood stage vaccine candidate, Cysteine-Rich Protective Antigen (CyRPA)
EP2409987B1 (en) Ribosomal P protein complex from Plasmodium falciparum as antigen in vaccines against malaria
EP2501717B1 (en) Enhanced malaria msp-1 subunit vaccine
EP1808443A1 (en) Purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from Plasmodium falciparum carrying a Glycosyl-phosphatidyl-inositol group (GPI)
Boes et al. LLLLGGG GGGGGGG GGG LLL GGGGGG
Wu et al. Malaria Vaccine Development

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201027